- Home
- MPW vs CPRX Comparison
MPW vs CPRX Comparison
Compare MPW & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPW | CPRX |
|---|---|---|
| Founded | 2003 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | 2005 | 2006 |
Fundamental Metrics
Financial Performance| Metric | MPW | CPRX |
|---|---|---|
| Price | $5.38 | $22.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $5.88 | ★ $32.60 |
| AVG Volume (30 Days) | ★ 6.3M | 1.3M |
| Earning Date | 02-26-2026 | 02-25-2026 |
| Dividend Yield | ★ 6.23% | N/A |
| EPS Growth | N/A | ★ 44.94 |
| EPS | N/A | ★ 1.71 |
| Revenue | ★ $1,009,160,000.00 | $578,196,000.00 |
| Revenue This Year | N/A | $19.87 |
| Revenue Next Year | $7.73 | $7.21 |
| P/E Ratio | ★ N/A | $13.22 |
| Revenue Growth | ★ 52.52 | 25.56 |
| 52 Week Low | $3.51 | $19.05 |
| 52 Week High | $6.34 | $26.58 |
Technical Indicators
Market Signals| Indicator | MPW | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.78 | 42.39 |
| Support Level | $4.98 | $22.15 |
| Resistance Level | $5.12 | $24.45 |
| Average True Range (ATR) | 0.13 | 0.62 |
| MACD | 0.03 | -0.22 |
| Stochastic Oscillator | 70.29 | 23.57 |
Price Performance
Historical ComparisonAbout MPW Medical Properties Trust Inc. common stock
Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. The group's geographic areas are the United States, the United Kingdom, and All other countries.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).